Q-linea receives positive response from the FDA for the design of the company's planned clinical study in the USA
Q-linea AB (publ) (OMX: QLINEA, announced today that the company has received the official response including a number of clarifications and very positive feedback from the US Food and Drug Administration, FDA, regarding the company's planned pivotal clinical trial with ASTar® in the United States.“We are very pleased with the official feedback from the FDA which will have a very positive impact on the conduct of our clinical study in the US. We have received the clear guidance we wanted and we believe that the study can be carried out in a more straightforward way than previously estimated,